Rezolute’s (RZLT) Buy Rating Reaffirmed at Guggenheim

Rezolute (NASDAQ:RZLT)‘s stock had its “buy” rating reissued by equities researchers at Guggenheim in a research note issued on Monday,Benzinga reports.

Several other research analysts also recently commented on the company. Craig Hallum raised Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Wednesday, February 5th. Finally, Wedbush reissued an “outperform” rating and set a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Rezolute presently has a consensus rating of “Buy” and a consensus target price of $24.13.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $4.86 on Monday. The stock has a market capitalization of $281.53 million, a PE ratio of -3.83 and a beta of 1.10. Rezolute has a fifty-two week low of $1.04 and a fifty-two week high of $6.19. The business has a fifty day moving average price of $4.90 and a two-hundred day moving average price of $4.90.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. On average, equities analysts expect that Rezolute will post -0.99 EPS for the current year.

Insider Activity

In other news, CFO Daron Evans bought 9,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $4.60 per share, with a total value of $41,400.00. Following the completion of the transaction, the chief financial officer now directly owns 140,900 shares of the company’s stock, valued at $648,140. This trade represents a 6.82 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 18.39% of the stock is currently owned by company insiders.

Institutional Trading of Rezolute

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Rezolute by 39.0% during the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock worth $2,385,000 after purchasing an additional 137,905 shares during the period. Exome Asset Management LLC grew its position in shares of Rezolute by 24.7% during the 3rd quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock valued at $1,707,000 after acquiring an additional 69,656 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Rezolute during the 2nd quarter worth approximately $255,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Rezolute in the 3rd quarter worth approximately $239,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Rezolute by 366.0% in the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the last quarter. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.